Reuters is reporting that pharmaceutical companies may be shifting the amount of taxes they owe in the United States by holding their valuable drug patents overseas.
Reuters is reporting that pharmaceutical companies may be shifting the amount of taxes they owe in the United States by holding their valuable drug patents overseas.
When the Trump administration cut the corporate tax rate to 21% from 35% with the approval of the Tax Cuts and Jobs Act, the rationale for the cut was putting a halt to outsourcing and providing an incentive for companies to keep businesses and jobs within the United States. However, drug companies like AbbVie, indicated Reuters, may be using loopholes within the law to profit from the change.
Richard Gonzalez, AbbVie’s CEO, told investors earlier this year that, due to the tax cut (which requires only profits reported by domestic subsidiaries to pay US tax), the company expects its tax rate to fall to 9% on a projected revenue of $32 billion.
Despite basing most of its research facilities in the United States, Reuters indicates that AbbVie has never recorded a profit in the United States and has reported its income in lower-tax jurisdictions, in part due to holding 88 patents for adalimumab (Humira) in Bermuda, a country that does not tax corporate profits.
In 2017, AbbVie reported $10.4 billion of foreign profits before taxes on an international revenue of $9.97 billion. Conversely, from 2013 to 2016, AbbVie reportedly paid around $1 billion a year in taxes in the United States when it took earnings reported by foreign subsidies back home to cover expenses from US-based facilities.
To avoid such profit-shifting, the government attached a provision to the Tax Cuts and Jobs Act called Global Intangible Low Tax Income (GILTI). The provision states that if a company profits from a so-called tax haven, it will be liable to have the profit taxed as income generated in the United States. However, the tax rate that applies is only half the US tax rate.
Though the exact process utilized by AbbVie to report such low tax rates is not disclosed to the public, analysts and academics within the field have noted that corporate filings often show drug companies reduce taxes by holding patents in a low or zero corporate tax country. Using this method, the affiliate companies which manufacture or market the drug pay the tax haven subsidiary royalty fees for the right to use the patent.
AbbVie is not the only pharmaceutical company benefitting from the new tax law. Amgen has reported a 14% to 15% tax rate for 2018, comparable to 17% for Pfizer and 18% for Eli Lilly.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.